The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Open accessPublished version of a preprint
Abstract
UNLABELLED: Patients with pancreatic and biliary carcinomas lack personalized treatment options, in part because biopsies are often inadequate for molecular characterization. Cell-free DNA (cfDNA) sequencing may enable a precision oncology approach in this setting. We attempted to prospectively analyze 54 genes in tumor and cfDNA for 26 patients. Tumor sequencing failed in 9 patients (35%). In the remaining 17, 90.3% (95% confidence interval, 73.1%-97.5%) of mutations detected in tumor biopsies were also detected in cfDNA. The diagnostic accuracy of cfDNA sequencing was 97.7%, with 92.3% average sensitivity and 100% specificity across five informative genes. Changes in cfDNA correlated well with tumor marker dynamics in serial sampling (r = 0.93). We demonstrate that cfDNA sequencing is feasible, accurate, and sensitive in identifying tumor-derived mutations without prior knowledge of tumor genotype or the abundance of circulating tumor DNA. cfDNA sequencing should be considered in pancreatobiliary cancer trials where tissue sampling is unsafe, infeasible, or otherwise unsuccessful. SIGNIFICANCE: Precision medicine efforts in biliary and pancreatic cancers have been frustrated by difficulties in obtaining adequate tumor tissue for next-generation sequencing. cfDNA sequencing reliably and accurately detects tumor-derived mutations, paving the way for precision oncology approaches in these deadly diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar to other reports for tissue NGS (46), quantity of tDNA was not sufficient for 24 of 52 (46.2%) patients.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J. W., Wasan, H. S., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T. J., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,423
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · cited 1×
“As a result, most genomic research in PDA has centered around tumor-derived cell lines or xenografts in lieu of direct tumor sequencing(7), and expert bodies currently make no recommendations regarding molecular profiling for clinical decision-making in PDA(8), despite potentially sensitive subsets identified by seque…”
BackgroundRyan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348
Cited by
Sorted by citations
Items 101–200 of 281
Diagnostic and Prognostic Value of Circulating Cell-Free DNA for Cholangiocarcinoma
Wintachai, P., Lim, J. Q., Techasen, A., Lert-itthiporn, W., Kongpetch, S., Loilome, W., Chindaprasirt, J., Titapun, A., Namwat, N., Khuntikeo, N., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11060999 · Cited by 37
Application of Circulating Tumor DNA as a Biomarker for Non-Small Cell Lung Cancer
Yang, J., Yan, H., Zhang, Y.-X., Zhang, M., Ji, B., Tian, G., Guo, Y., Tang, M., Li, L., Guo, B., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.725938 · Cited by 37
Hussung, S., Akhoundova, D., Hipp, J., Follo, M., Klar, R. F. U., Philipp, U., Scherer, F., von Bubnoff, N. C. C., Duyster, J., Boerries, M., et al. (2021) · BMC Cancer · doi:10.1186/s12885-020-07736-x · Cited by 38
Biomarkers, omics and artificial intelligence for early detection of pancreatic cancer
Murray, K., Oldfield, L. S., Stefanova, I., Gentiluomo, M., Aretini, P., O’Sullivan, R., Greenhalf, W., Paiella, S., Aoki, M. N., Pastore, A., et al. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.02.009 · Cited by 38
Circulating Tumor Cells and Circulating Tumor DNA
Lianidou, E. S., & Hoon, D. S. �. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-816061-9.00009-6 · Cited by 36
Exosome-specific tumor diagnosis via biomedical analysis of exosome-containing microRNA biomarkers
Fan, Z., Yu, J., Lin, J., Liu, Y., & Liao, Y. (2019) · The Analyst · doi:10.1039/c9an00777f · Cited by 36
Precision medicine in pancreatic cancer — fact or fiction?
Seufferlein, T., & Mayerle, J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.215 · Cited by 35
The Omics Revolution Continues: The Maturation of High-Throughput Biological Data Sources
Mathé, E. A., Hays, J. L., Stover, D. G., & Chen, J. L. (2018) · Yearbook of Medical Informatics · doi:10.1055/s-0038-1667085 · Cited by 33
PRECISION-Panc: the Next Generation Therapeutic Development Platform for Pancreatic Cancer
Dreyer, S. B., Jamieson, N. B., Cooke, S. L., Valle, J. W., McKay, C. J., Biankin, A. V., & Chang, D. K.-F. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.07.011 · Cited by 35
García‐Ortiz, M. V., Cano-Ramírez, P., Toledano‐Fonseca, M., Aranda, E., & Rodríguez‐Ariza, A. (2023) · Biomarker Research · doi:10.1186/s40364-023-00528-y · Cited by 35
The Role of Next-Generation Sequencing in the Cytologic Diagnosis of Pancreatic Lesions
de Biase, D., Visani, M., Acquaviva, G., Fornelli, A., Masetti, M., Fabbri, C., Pession, A., & Tallini, G. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0215-ra · Cited by 34
Development of circulating tumour DNA analysis for gastrointestinal cancers
Nakamura, Y., & Shitara, K. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000600 · Cited by 33
Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer
Umemoto, K., Sunakawa, Y., Ueno, M., Furukawa, M., Mizuno, N., Sudo, K., Kawamoto, Y., Kajiwara, T., Ohtsubo, K., Okano, N., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02189-y · Cited by 35
Emerging role of precision medicine in biliary tract cancers
Bogenberger, J. M., DeLeon, T., Arora, M., Ahn, D. H., & Borad, M. J. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0064-z · Cited by 32
Roukos, D. H. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.03.014 · Cited by 32
Clinical and Translational Research Challenges in Biliary Tract Cancers
Lamarca, Á., Frizziero, M., McNamara, M. G., & Valle, J. W. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200123090153 · Cited by 30
Next-generation sequencing for the general cancer patient.
Avila, M., & Meric‐Bernstam, F. (2019) · PubMed · Cited by 30
Gupta, A., Kurzrock, R., & Adashek, J. J. (2023) · Cancers · doi:10.3390/cancers15051578 · Cited by 29
Wehrle, C. J., Raj, R., Aykun, N., Orabi, D., Stackhouse, K. A., Chang, J. H., Estfan, B. N., Kamath, S. D., Krishnamurthi, S., Walsh, R. M., et al. (2023) · JCO Clinical Cancer Informatics · doi:10.1200/cci.23.00111 · Cited by 29
Au, T. H., Wang, K., Stenehjem, D. D., & Garrido‐Laguna, I. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.01.04 · Cited by 29
Tian, X., Ge, D., Zhang, F., Zhang, B., Bai, W., Xu, X., Li, Z., Cao, Y., Li, P., Zou, K., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33362 · Cited by 28
Arrichiello, G., Nacca, V., Paragliola, F., & Giunta, E. F. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00087 · Cited by 27
Mehrotra, M., Singh, R. R., Chen, W., Huang, R. S. P., Almohammedsalim, A. A., Barkoh, B. A., Simien, C. M., Hernandez, M., Behrens, C., Patel, K. P., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.03.003 · Cited by 28
Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC)
Chen, H., Yang, G., Xiao, J., Zheng, L., You, L., & Zhang, T. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.011 · Cited by 30
Pancreatic cancer: Are "liquid biopsies" ready for prime-time?
Lewis, A. R., Valle, J. W., & McNamara, M. G. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i32.7175 · Cited by 31
Liquid biopsy using extracellular vesicle–derived DNA in lung adenocarcinoma
Kim, I. A., Hur, J. Y., Kim, H. J., Lee, S. E., Kim, W. S., & Lee, K. Y. (2020) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2020.08.13 · Cited by 26
Advances in the Genetics and Biology of Pancreatic Cancer
Aguirre, A. J., & Collisson, E. A. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000286 · Cited by 23
Pietrasz, D., Sereni, E., Lancellotti, F., Pea, A., Luchini, C., Innamorati, G., Salvia, R., & Bassi, C. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01745-2 · Cited by 25
Research progress of bile biomarkers and their immunoregulatory role in biliary tract cancers
Li, Y., Li, K.-S., Liu, Z., Tang, Y., Hu, X., Li, X.-Y., Shi, A., Zhao, L., Shu, L., Lian, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1049812 · Cited by 23
Connor, A. A., Kodali, S., Abdelrahim, M., Javle, M. M., Brombosz, E. W., & Ghobrial, R. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.996710 · Cited by 23
Bestari, M. B., Joewono, I. R., & Syam, A. F. (2024) · Biomolecules · doi:10.3390/biom14030364 · Cited by 24
Moravec, R., Divi, R. L., & Verma, M. (2017) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v9.i6.235 · Cited by 24
Rofi, E., Vivaldi, C., Re, M. D., Arrigoni, E., Crucitta, S., Funel, N., Fogli, S., Vasile, E., Musettini, G., Fornaro, L., et al. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0149 · Cited by 25
No association between metformin use and survival in patients with pancreatic cancer
Frouws, M. A., Mulder, B. G. S., Bastiaannet, E., Zanders, M. M. J., van Herk‐Sukel, M. P. P., de Leede, E. M., Bonsing, B. A., Mieog, J. S. D., van de Velde, C. J. �., & Liefers, G. (2017) · Medicine · doi:10.1097/md.0000000000006229 · Cited by 22
Kamp, E. J. C. A., Dinjens, W. N. M., Doukas, M., Bruno, M. J., de Jonge, P. J. F., Peppelenbosch, M. P., & de Vries, A. C. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211002023 · Cited by 24
Bile liquid biopsy in biliary tract cancer
Liu, F., Hao, X., Liu, B., Liu, S., & Yuan, Y. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117593 · Cited by 23
Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management
Lieu, C. H., Corcoran, R. B., & Overman, M. J. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240839 · Cited by 22
Precision oncology in biliary tract cancer: the emerging role of liquid biopsy
de Scordilli, M., Bortolot, M., Torresan, S., Noto, C., Rota, S., Nardo, P. D., Fumagalli, A., Guardascione, M., Ongaro, E., Foltran, L., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105079 · Cited by 21
Chen, C., Wang, T., Yang, M., Song, J. T., Huang, M., Bai, Y., & Su, H. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.1609879 · Cited by 21
Guan, S., Deng, G., Sun, J., Han, Q., Lv, Y., Xue, T., Ding, L., Yang, T., Qian, N., & Dai, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.926260 · Cited by 21
The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal Cancers
Lee, M. S., Kaseb, A. O., & Pant, S. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3626 · Cited by 21
Lee, S. H., & Song, S. Y. (2024) · Cancers · doi:10.3390/cancers16091761 · Cited by 22
Recent technologies enhancing the clinical utility of circulating tumor DNA
Manoharan, A., Ravikumar, S., & Bhat, V. B. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.08.010 · Cited by 20
Circulating Tumor Cells and Circulating Tumor DNA Provide New Insights into Pancreatic Cancer
Gao, Y., Zhu, Y., & Yuan, Z. (2016) · International Journal of Medical Sciences · doi:10.7150/ijms.16734 · Cited by 21
Daya, S. A., & Mahfouz, R. A. (2018) · Meta Gene · doi:10.1016/j.mgene.2018.06.013 · Cited by 20
Reviews on Current Liquid Biopsy for Detection and Management of Pancreatic Cancers
Kaczor‐Urbanowicz, K. E., Cheng, J. C., King, J. C., Sedarat, A., Pandol, S. J., Farrell, J. J., Wong, D. T., & Kim, Y. H. (2020) · Pancreas · doi:10.1097/mpa.0000000000001662 · Cited by 23
Circulating tumor DNA in cholangiocarcinoma: current clinical applications and future perspectives
Wang, J., Li, Y., Liang, Z., Zhang, Y., Li, T., Tian, C., Zhao, J., Jin, B., Cao, J., & Lin, Y. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1616064 · Cited by 21
Nikas, I. P., Mountzios, G., Sydney, G. I., Ioakim, K. J., Won, J., & Papageorgis, P. (2022) · Cancers · doi:10.3390/cancers14020397 · Cited by 22
Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas
Dhayat, S. A., & Yang, Z. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03219-5 · Cited by 19
Cell-free DNA testing for the detection and prognosis prediction of pancreatic cancer
Wu, J., Xu, X., Zhang, Q., Li, P., Wu, T., Guo, S., Du, L., Xue, D., Shen, S., Sun, F.-M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61890-z · Cited by 23
Choi, W. J., Ivanics, T., Gravely, A., Gallinger, S., Sapisochín, G., & O'Kane, G. M. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13126-x · Cited by 18
Derazantinib: an investigational drug for the treatment of cholangiocarcinoma
Braun, S., McSheehy, P. M. J., Litherland, K., McKernan, P., Forster-Gross, N., Bachmann, F., El‐Shemerly, M., Dimova-Dobreva, M., Polyakova, I., Häckl, M., et al. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1995355 · Cited by 18
Novel Biomarkers in the Diagnosis of Benign and Malignant Gastrointestinal Diseases
Jonaitis, P., Kiudelis, V., Streleckienė, G., Gedgaudas, R., Skiecevičienė, J., & Kupčinskas, J. (2021) · Digestive Diseases · doi:10.1159/000515522 · Cited by 17
Targeted therapies in advanced biliary tract cancers—a narrative review
LaPelusa, M. B., Heumann, T. R., Goff, L. W., & Agarwal, R. (2023) · Chinese Clinical Oncology · doi:10.21037/cco-22-93 · Cited by 18
Implementing Liquid Biopsies in Clinical Trials
Lustberg, M. B., Stover, D. G., & Chalmers, J. J. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000309 · Cited by 17
Affolter, K. E., Hellwig, S., Nix, D. A., Bronner, M. P., Thomas, A., Fuertes, C. L., Hamil, C. L., Garrido‐Laguna, I., Scaife, C. L., Mulvihill, S. J., et al. (2021) · Neoplasia · doi:10.1016/j.neo.2021.06.005 · Cited by 16
Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake
Golan, T., Casolino, R., Biankin, A. V., Hammel, P. R., Whitaker, K. D., Hall, M. J., & Riegert‐Johnson, D. L. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231189127 · Cited by 16
Wang, X., Fu, X., Qian, Z., Zhao, T., Duan, A., Ruan, X., Zhu, B., Yin, L., Zhang, Y., & Yu, W. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100908 · Cited by 16
Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma
Zhang, Y., Liu, Z., Ji, K., Li, X., Wang, C., Ren, Z., Liu, Y., Chen, X., Han, X., Meng, L., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.736330 · Cited by 16
Clinical applications of liquid biopsies in gastrointestinal oncology
Zhu, J., & Strickler, J. H. (2016) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.08.08 · Cited by 15
Circulating tumor DNA for diagnosis, prognosis and treatment of gastrointestinal malignancies
Kirchweger, P., Wundsam, H., & Rumpold, H. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i6.473 · Cited by 15
State of the Art: ctDNA in Upper Gastrointestinal Malignancies
Labiano, I., Huerta, A. E., Arrazubi, V., Hernández-García, I., Mata, E., Gómez, D., Arasanz, H., Vera, R., & Alsina, M. (2023) · Cancers · doi:10.3390/cancers15051379 · Cited by 15
Ziogas, D. E., Kyrochristos, I. D., & Roukos, D. H. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.07.008 · Cited by 15
Wang, Z., Shi, Y., Xiong, G., Han, M., & Chen, X. (2024) · Discover Oncology · doi:10.1007/s12672-024-01683-w · Cited by 14
Ivosidenib: an investigational drug for the treatment of biliary tract cancers
Angelakas, A., Lamarca, Á., Hubner, R. A., McNamara, M. G., & Valle, J. W. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1900115 · Cited by 15
Kanai, M. (2022) · Current Oncology · doi:10.3390/curroncol29100573 · Cited by 14
Shotton, R., Lamarca, Á., Valle, J. W., & McNamara, M. G. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i9.1073 · Cited by 14
Novel technologies in cfDNA analysis and potential utility in clinic
Li, J., Xu, M., Peng, J., Wang, J., Zhao, Y., Wu, W., & Lan, X. (2021) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2021.06.07 · Cited by 15
Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes
Tsumura, T., Doi, K., & Marusawa, H. (2022) · Cancers · doi:10.3390/cancers14153674 · Cited by 15
Cell free DNA in patients with pancreatic adenocarcinoma: clinicopathologic correlations
Theparee, T., Akroush, M., Sabatini, L. M., Wang, V., Mangold, K. A., Joseph, N. E., Stocker, S. J., Freedman, A. A., Helseth, D. L., Talamonti, M. S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-65562-8 · Cited by 13
Rosenberg, S., Okamura, R., Kato, S., Soussi, T., & Kurzrock, R. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0097 · Cited by 13
Kim, K., Yi, H., Lee, H.-J., Bae, G.-E., & Yeo, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087512 · Cited by 13
Thakral, D., Das, N., Basnal, A., & Gupta, R. (2020) · PubMed · Cited by 16
Cholangiocarcinoma: The era of liquid biopsy
Kotsifa, E., Saffioti, F., & Mavroeidis, V. K. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i11.104170 · Cited by 12
Liquid biopsy in gallbladder carcinoma: Current evidence and future prospective
Mishra, S., Kumari, S., & Husain, N. (2024) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2024.100280 · Cited by 12
Cell-free DNA testing: future applications in gastroenterology and hepatology
Zandvakili, I., & Lazaridis, K. N. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819841896 · Cited by 12
Circulating Cell-Free DNA in Pancreatic Head Adenocarcinoma Undergoing Pancreaticoduodenectomy
Wang, S., Shyr, B., Shyr, B., Chen, S., Chang, S., & Shyr, Y. (2021) · Pancreas · doi:10.1097/mpa.0000000000001730 · Cited by 11
Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA
Sánchez, N., Kahle, M., Bailey, A. M., Wathoo, C., Balaji, K., Demirhan, M. E., Yang, D., Javle, M. M., Kaseb, A. O., Eng, C., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00017 · Cited by 11
Expanded knowledge of cell-free DNA biology: potential to broaden the clinical utility
Che, H., Stanley, K., Jatsenko, T., Thienpont, B., & Vermeesch, J. R. (2022) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2022.21 · Cited by 9
Circulating Tumor DNA: Clinical Monitoring and Early Detection
Corcoran, R. B. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055719 · Cited by 10
Portal-vein blood samples as a new diagnostic entity for pancreatic cancer
Chapman, C. G., & Waxman, I. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2016.1176911 · Cited by 10
Jiao, X., Ding, L., Zhang, C., Qin, B., Liu, K., Jiang, L.-P., Wang, X., Lv, L., Ding, H., Li, D., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-543 · Cited by 9
Fang, Q., Wan, X., D’Aiello, A., Sun, H., Gu, W., Li, Y., Zhou, C., Xie, B., Deng, Q., Cheng, H., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1116809 · Cited by 9
Key challenges for drugs in clinical development for cholangiocarcinoma
Keenan, B. P., & Kelley, R. K. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1880565 · Cited by 10
Taklifi, P., Palizban, F., & Mehrmohamadi, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-14675-z · Cited by 8
Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma
Keane, F., Saadat, L. V., O'Connor, C. A., Chou, J. F., Bowman, A. S., Xu, F., Crowley, F., Debnath, N., Schoenfeld, J. D., Singhal, A., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf139 · Cited by 10
Liquid Biopsy in Pancreatic Ductal Adenocarcinoma: Clinical Utility, Trials, and Future Directions
Bendari, A., Vele, O. E., Baskovich, B. W., Bendari, A., Sebika, M., Marti, J. L. G., Krishnamurthy, K., & Asiry, S. (2025) · Gastroenterology Insights · doi:10.3390/gastroent16040039 · Cited by 8
Koo, B., Jun, E., Liu, H., Kim, E. J., Park, Y., Lim, S., Kim, S. C., & Shin, Y. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-72163-8 · Cited by 8
Liquid biopsy in pancreatic cancer: current advances, limitations, and future perspectives
Carrara, S., Bevere, M., Cave, D. D., Gentiluomo, M., Esposito, I., & Luchini, C. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.03.002 · Cited by 7
Liver transplantation and intrahepatic cholangiocarcinoma: time to go forward again?
Kodali, S., Saharia, A., & Ghobrial, R. M. (2022) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000000983 · Cited by 7
Paturu, R., Lingaiah, R., Kumari, N., Singh, S., Krishnani, N., Srivastava, S., Siddiqui, S., & Nath, A. (2023) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2023.24.10.3467 · Cited by 7
Novel biomarkers and endoscopic techniques for diagnosing pancreaticobiliary malignancy
Keane, M. G., Shah, A., Pereira, S. P., & Joshi, D. (2017) · F1000Research · doi:10.12688/f1000research.11371.1 · Cited by 7
Clinical Applications of Circulating Tumour DNA in Pancreatic Adenocarcinoma
Loft, M., Lee, B., Tie, J., & Gibbs, P. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9030037 · Cited by 7
Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer
Merz, V., Mangiameli, D., Zecchetto, C., Quinzii, A., Pietrobono, S., Messina, C. G. M., Casalino, S., Gaule, M., Pesoni, C., Vitale, P., et al. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.866173 · Cited by 7
Evans, M., & Kendall, T. J. (2024) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2024.2353696 · Cited by 6
Pancreatic ductal adenocarcinoma: the role of circulating tumor DNA
Habib, J. R., Yin, L., & Yu, J. (2019) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000021 · Cited by 6
Rosenberg, S., Cohen, G. B., Kato, S., Okamura, R., Lippman, S. M., & Kurzrock, R. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13383 · Cited by 6
Available technologies and clinical applications of targeted chemotherapy in pancreatic cancer
Mukherjee, I., Powell, B., Parianos, M., Downs, D. J., & Ross, S. B. (2016) · Cancer Genetics · doi:10.1016/j.cancergen.2016.08.001 · Cited by 6
Prognostic Role of Circulating DNA in Biliary Tract Cancers: A Systematic Review and Meta-Analysis
Boggio, S., Alaimo, L., Poletto, E., Quinzii, A., Scoccati, G., Bellis, M. D., Conci, S., Campagnaro, T., & Ruzzenente, A. (2025) · Cancers · doi:10.3390/cancers17213451 · Cited by 5
Guo, C., Zhang, J., Zhang, S., Moon, J., Yang, R., Guan, X., Hou, C., Pei, M., Schalper, K. T., Schreiber, D., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-66893-4 · Cited by 5
Metadata
- Authors
- Zill, O. A., Greene, C., Sebisanovic, D., Siew, L. M., Leng, J., Vu, M., Hendifar, A. E., Wang, Z., Atreya, C. E., Kelley, R. K., Van Loon, K., Ko, A. H., Tempero, M. A., Bivona, T. G., Munster, P. N., Talasaz, A., & Collisson, E. A.
- Affiliations
- University of California, San Francisco (US)
- Guardant (United States) (US)
- University of South Alabama (US)
- Cedars-Sinai Medical Center (US)
- 2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
- Corresponding author
- Collisson, Eric A.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2015-09-30
- Volume
- 5
- Issue
- 10
- Pages
- 1040-1048
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC4592417
- OpenAlex
- W2113754052
- Cited by
- 282
- References
- 31
- Citations by year
- 2026: 11 · 2025: 20 · 2024: 16 · 2023: 29 · 2022: 21 · 2021: 31 · 2020: 29 · 2019: 30 · 2018: 35 · 2017: 31 · 2016: 21 · 2015: 8
- FWCI
- 10.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (DP2CA174497, K08CA175153)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Keywords
- cell-free DNA sequencing, circulating tumor DNA, pancreatic cancer, biliary tract cancer, precision oncology, tumor mutation detection, diagnostic accuracy, tumor markers, liquid biopsy
- MeSH terms
- Bile Duct Neoplasms, Carcinoma, DNA, Neoplasm, Humans, Mutation, Neoplasm Staging, Pancreatic Neoplasms, Prognosis, Sensitivity and Specificity, Biomarkers, Tumor, Reproducibility of Results, Disease Progression, Gene Expression Profiling, High-Throughput Nucleotide Sequencing, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
